Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 37 of the 55 sources its claims cite were checked for support.
Abstract
mice, were largely maintained during spaceflight. Systemic inhibition of MSTN/activin A signaling using a soluble form of the activin type IIB receptor (ACVR2B), which can bind each of these ligands, led to dramatic increases in both muscle and bone mass, with effects being comparable in ground and flight mice. Exposure to microgravity and treatment with the soluble receptor each led to alterations in numerous signaling pathways, which were reflected in changes in levels of key signaling components in the blood as well as their RNA expression levels in muscle and bone. These findings have implications for therapeutic strategies to combat the concomitant muscle and bone loss occurring in people afflicted with disuse atrophy on Earth as well as in astronauts in space, especially during prolonged missions.
Overview
CoChat Summary
## TL;DR
This mouse ISS study tested whether blocking myostatin/activin A signaling with ACVR2B/Fc or genetic Mstn deletion could protect against microgravity-induced muscle and bone loss. The paper reports that ACVR2B/Fc significantly increased lean mass and bone measures in flight mice and helped restore both muscle and bone after return to Earth.
## Key findings
- Muscle loss from spaceflight: In wild type mice exposed to microgravity for 33 days, lean body mass was 9% lower, and weights of the pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus were 8%, 8%, 15%, 14%, and 18% lower, respectively, than ground controls.
- ACVR2B/Fc improved muscle growth in flight: In flight mice, lean body mass increased by 27% over 22 days after ACVR2B/Fc treatment, compared with 18% in ground mice over the same interval; individual muscle weights at return were significantly higher than in uninjected flight mice.
- Bone loss from spaceflight and protection by ACVR2B/Fc: In uninjected flight mice, whole-body, left femur, and right femur BMD fell by 8%, 11%, and 8% over 22 days in microgravity. ACVR2B/Fc increased BMD in ground mice by 4%, 10%, and 9% and brought BMD in flight mice to levels comparable to uninjected ground mice.
- MicroCT showed strong skeletal protection: In femurs of uninjected flight mice, BV/TV, trabecular thickness, trabecular number, and cortical thickness were reduced by 37%, 8%, 9%, and 9%; ACVR2B/Fc increased these in ground mice by 96%, 10%, 31%, and 12%, and in flight mice the femoral BV/TV and trabecular number were described as nearly indistinguishable from ACVR2B/Fc-treated ground mice.
- Recovery after return to Earth: After 2 weeks on Earth, untreated mice recovered muscle mass to baseline, but ACVR2B/Fc further increased muscle weights to 39%, 36%, 34%, 26%, and 20% above baseline for pectoralis, triceps, quadriceps, gastrocnemius/plantaris, and soleus, respectively; bone mass also showed conservation or gain with treatment.
## Methods
- Design and sample: The study sent 40 female mice to the ISS in five groups of eight: untreated wild type, ACVR2B/Fc-treated wild type, and Mstn−/− mice, plus additional wild type groups kept on Earth for postflight recovery; there were also 24 ground control mice matched to flight conditions.
- Intervention and timing: ACVR2B/Fc was administered intraperitoneally at 175 μg per injection on scheduled days before/during/after flight; mice were analyzed either at live animal return or after 14 days of recovery on Earth.
- Main analyses: The paper used DXA, microCT, RNAseq, SomaScan proteomics, and ELISA to assess muscle, bone, and pathway changes.
## Limitations
- The authors state that additional studies will be required to understand the basis of the unexpected higher humerus BMD seen early in flight, so that result remains unexplained in the paper.
- They state they did not measure body water content, so the apparent rapid postflight muscle recovery could partly reflect water shifts rather than true tissue recovery.
- Evidence evident from the text: the study used female mice only, so direct generalization to males is not supported by the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
27 Valid · 1 Not valid · 4 Not checked · 73 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33–35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Not checked — no full text of the sourcecites [33] Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 423, 337– 342 (2003). 12748652 source
- Not checked — no full text of the sourcecites [34] Zauli G.., TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J. Cell. Physiol. 214, 117– 125 (2008). 17620297 source
- Partly supportedcites [35] Baud’huin M.., Osteoprotegerin: Multiple partners for multiple functions. Cytokine Growth Factor Rev. 24, 401– 409 (2013). 23827649 sourceExperimental — accuracy not yet measured
The citation is attached to the premise about osteoclast differentiation and survival; the ACVR2B/Fc mechanism is the citing authors’ own inference. In “RANKL and TRAIL: ligands from the TNF family” (page unavailable), the source says RANKL–RANK signaling regulates osteoclast differentiation and survival, but it does not establish the same role for TRAIL. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“We showed previously that treatment with ACVR2B/Fc can induce rapid muscle growth (13), and indeed, the decoy receptor increased lean body mass in ground mice by 11% in just 12 d (Fig. 1D).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [13] Lee S.-J.., Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U.S.A. 102, 18117– 18122 (2005). 16330774 PMC1306793 source
The citation is attached to the statement that ACVR2B/Fc can induce rapid muscle growth. The source’s Results and Discussion report that its maximal effect was reached after two injections spaced one week apart. The 11% increase in lean body mass over 12 days is attributed to the citing paper’s Fig. 1D, not to this source. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, BMD in the humerus was not reduced in flight mice during this 22 d period, consistent with the differential effects of microgravity on the femur and humerus reported in rats (26) and humans (27).”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Results and Discussion
What the sources say
- Supportedcites [26] Keune J. A., Branscum A. J., Iwaniec U. T., Turner R. T., Effects of spaceflight on bone microarchitecture in the axial and appendicular skeleton in growing ovariectomized rats. Sci. Rep. 5, 18671 (2015). 26691062 PMC4687043 source
The citation is attached to the differential effects on femur and humerus in rats, not to the citing authors’ observation about mice during a 22-day period. The Results sections report lower femur BMD in flight rats but no significant effect of spaceflight on humerus BMD. (LLM, conf=0.93)
- Supportedcites [27] Stavnichuk M., Mikolajewicz N., Corlett T., Morris M., Komarova S. V., A systematic review and meta-analysis of bone loss in space travelers. NPJ Microgravity 6, 13 (2020). 32411816 PMC7200725 source
The citation is attached to the comparison with humans, not the citing paper’s finding in 22-day flight mice. In Results, under “Skeletal site-specific changes in bone density” (page unavailable), the source reports substantially greater bone loss in the lower limbs than in the upper-limb/thorax region of space travelers, supporting the stated differential effect. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility (21,”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [21] DiGirolamo D. J., Singhal V., Chang X., Lee S. J., Germain-Lee E. L., Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Res. 3, 14042 (2015). 26161291 PMC4472144 source
The Results (page not supplied) report significant increases in trabecular bone measures and in several muscle weights after ACVR2B treatment of oim mice. The Introduction identifies this model as having deficits in muscle mass and function, while the Discussion describes low bone mass and fractures alongside muscle atrophy. The paper supports effectiveness for increasing bone and muscle mass; it does not establish improved fracture resistance. (LLM, conf=0.91)
- Partly supportedcites [22] Jeong Y.., Skeletal response to soluble activin receptor type IIB in mouse models of osteogenesis imperfecta. J. Bone Miner. Res. 33, 1760– 1772 (2018). 29813187 PMC6400483 sourceExperimental — accuracy not yet measured
The Results report increased skeletal muscle mass with sActRIIB-mFc treatment, and the Discussion reports improved trabecular bone architecture in both OI mouse models. The paper documents bone fragility, but the passages found do not establish that these models are characterized by muscle atrophy; it also reports no reduction in fracture occurrence. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although advances in exercise devices and nutrition have significantly attenuated the bone mineral density losses observed during prolonged missions on vehicles like the International Space Station (ISS) (23, 24), future exploration missions to destinations like Mars will be significantly longer (∼3 y) and impose mass constraints that will not allow for the same, highly effective exercise”
§ Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight > Abstract
What the sources say
- Supportedcites [23] Smith S. M.., Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: Evidence from biochemistry and densitometry. J. Bone Miner. Res. 27, 1896– 1906 (2012). 22549960 source
The Abstract states that improved nutrition and resistance exercise attenuated the BMD deficits previously observed after prolonged missions. The Discussion reports that ISS crewmembers with sufficient resistance exercise and adequate nutrition returned from 4-to-6-month missions with BMD seemingly unchanged from baseline in most skeletal regions. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [24] Sibonga J.., Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. Bone 128, 112037 (2019). 31400472 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims · 2 with their cited sources checked
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 30
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“Because TRAIL and RANKL are known to regulate osteoclast differentiation and survival (33 – 35), these findings suggest that increased RANK (tumor necrosis factor receptor superfamily member 11a) signaling may be involved in the regulation of bone growth and remodeling induced by ACVR2B/Fc.…”
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Self-citationLDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235 · cited 1×
“Given that loss-of-function mutations in the Wnt receptor LRP5 results in low bone mass in both humans (47) and mice (48), the down-regulation of sFRP4, taken together with changes in levels of several Wnt inhibitors, suggests that altered Wnt signaling may play a role in bone loss resulting from exposure to micrograv…”
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Self-citationAptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“We carried out proteomic analysis of plasma using the SomaScan assay, which uses aptamers to measure relative levels of over 5,000 secreted proteins (31).”
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Signaling is initiated by binding of these ligands to the activin type II receptors, ACVR2 and ACVR2B (17).”
Self-citationSecreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 2×
“Nevertheless, given that Dickkopfs are secreted proteins capable of antagonizing Wnt signaling by inhibiting the coreceptors LRP5 and LRP6 (43, 44), these findings suggest that increased Wnt signaling may also be involved in the increase in bone mass induced by ACVR2B/Fc.”
A deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399 · cited 1×
“Moreover, a heavily muscled boy was found to carry a mutation in a splice site in theMSTN gene, showing that MSTN plays a similar role in humans as well (12).”
Self-citationClop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260 · cited 1×
“The function of MSTN has been strongly conserved through evolution, as targeted or naturally occurring mutations in cattle (3–5), sheep (6), dogs (7), rabbits (8), rats (9), swine (10), and goats (11) have all been shown to lead to increased muscling.”
Cited by
Items 101–115 of 115
Gu, X., Wang, X., Yang, Y., Guan, K., Chang, H.-C., Liu, D., Wang, W., Wu, T., He, P., Wang, J., et al. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.70019
Biotechnology for a spacefaring civilization—necessary and challenging
Walker, C. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13850-8.00003-8
Targeting the Alk4 pathway protects against age-related bone lossPreprint
Maridas, D. E., Chim, S. M., Burton, K. M., Doren, E. V., Gamer, L., Kirshen, K., Keles, E., Avalos, K., Kethani, R. S., & Rosen, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684408
Herrera, R. J., & Garcia‐Bertrand, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28919-4.00014-3
The effect of spaceflight on tissues of the spinal column
Veres, J. E., Almeida, E. A. C., Bailey, J., & O’Connell, G. D. (2026) · Bone Reports · doi:10.1016/j.bonr.2025.101895
“Again, these finding conflicts with multiple spaceflight studies (Berg-Johansen et al., 2016; LeBlanc et al., 2000; Lang et al., 2004; Sibonga et al., 2007, 2019; Lee et al., 2020).”
Yuan, R., Wang, Y., Gao, W., Xiaojun, Y., Gu, J., Zheng, W., Liu, F., Li, T., & Zhang, T. (2026) · Aerospace · doi:10.3390/aerospace13020196
“The systems studied have included skeletal [3–5], muscular [6], nervous [7], cardiovascular [8], and immune [9–11].”
Chen, R., Dai, X., Wang, H., Zhang, T., Zhang, Z., Liu, Y., & Fan, Z. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1736069
“…a prominent interaction cluster centered on GDF11, featuring strong associations with activin receptors (ACVRs), particularly activin A receptor type 2B (ACVR2B), a well-established regulator of skeletal muscle mass and muscle atrophy (Hulmi et al., 2018; Lee et al., 2020) (Figures 5A,C).”
Self-citationIdentification of new levers to fight muscle atrophy : benefit of the hibernating brown bear model
Cussonneau, L. (2022) · theses.fr (ABES) · doi:10.70675/1a11a81bzf829z4ba2zba9az6f3f4841c773
Spaceflight and the rodent skeleton: A perspective
Monfared, V., Iwaniec, U. T., & Turner, R. T. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101917
“…variable and include normal weight gain, failure to gain weight and weight loss compared to baseline (Blaber et al., 2013; Coulombe et al., 2021; Dagdeviren et al., 2018; Gerbaix et al., 2017; Gerbaix et al., 2018; Hayashi et al., 2023; Lee et al., 2020; Wong et al., 2021; Zhang et al., 2013).”
Decoupling musculoskeletal integrity in microgravity: Molecular drivers and therapeutic horizons
Parkarwar, N., Dabhekar, S. V., Dwivedi, V., Taksande, B. G., Umekar, M. J., & Mangrulkar, S. V. (2026) · Life Sciences in Space Research · doi:10.1016/j.lssr.2026.04.009
Age-dependent musculoskeletal changes during mechanical unloading with bisphosphonate treatment
Orr, S. V., Gilmore, N. K., Pathak, S. J., Edan, H. A., Langer, H. T., Baar, K., & Christiansen, B. (2026) · Bone · doi:10.1016/j.bone.2026.117924
Andreev-Andrievskiy, A. A., Александрович, М. М., Drugova, S., Shurshakov, V., Викторович, П. Д., Tarasova, O. S., Buravkova, L. B., Виноградова, О. Л., Sychev, V. N., Orlov, O. I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.03.722490
“RTA-408-treated mice lost the least mass overall ( 15, 16 ), effectively preserving their antigravity muscles at ground-control levels — the most pronounced protective effect we observed in this study.”
Khamoui, A. V., Abraham, A., Pórszász, J., Kovanecz, I., Constantinescu, S., Rossiter, H. B., & Reisz‐Porszasz, S. (2026) · Experimental Physiology · doi:10.1113/ep093775 · Cited by 1
“…treatment (Latres et al., 2015), amyotrophic lateral sclerosis (Morrison et al., 2009), nemaline myopathy (Lindqvist & Granzier, 2023), sex-specific contractures (Emmert et al., 2022), spaceflight (Lee et al., 2020), and limb unloading and immobilization (Hanson et al., 2023; Latres et al., 2015).”
Ahmad, U. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1887696
Buccheri, E., Xourafa, A., Noto, M. D., Chiaramonte, R., Catalano, A., Castellino, P., Vecchio, M. M., & Gaudio, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177677
“Ligand-trap approaches using soluble recombinant ActRIIA or ActRIIB have been shown to increase bone and muscle mass, as well as strength, in animal models, even under conditions of disuse atrophy [36,37].”
Influential
Metadata
- Authors
- Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., Gogain, J., Michaud, M., Stoklasek, T. A., Liu, Y., & Germain-Lee, E. L.
- Affiliations
- University of Connecticut (US)
- The Jackson Laboratory for Genomic Medicine (US)
- National Aeronautics and Space Administration (US)
- Center for the Advancement of Science in Space (US)
- SomaLogic (United States) (US)
- Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030;
- Corresponding author
- Lee, Se-Jin
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-09-08
- Volume
- 117
- Issue
- 38
- Pages
- 23942-23951
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7519220
- OpenAlex
- W3084261347
- Cited by
- 115
- References
- 54
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 17 · 2023: 21 · 2022: 19 · 2021: 27 · 2020: 3
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- HHS | National Institutes of Health (R01AG052962, R01AR060636)
- Center for the Advancement of Science in Space (UA-2019-031)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Social Sciences › Political Science and International Relations › Space exploration and regulation
- Keywords
- myostatin, activin A, ACVR2B, microgravity, spaceflight, disuse atrophy, muscle atrophy, bone loss, skeletal muscle, bone mass, signaling pathways
- MeSH terms
- Animals, Bone Resorption, Female, Male, Mice, Inbred C57BL, Muscular Atrophy, Space Flight, Signal Transduction, Mice, Knockout, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.